Reaction Details Report a problem with these data
Target
IgG receptor FcRn large subunit p51
Ligand
BDBM50270959
Substrate
n/a
Meas. Tech.
ChEMBL_552584 (CHEMBL956456)
IC50
660±n/a nM
Citation
 Mezo, AR; McDonnell, KA; Castro, A; Fraley, C Structure-activity relationships of a peptide inhibitor of the human FcRn:human IgG interaction. Bioorg Med Chem 16:6394-405 (2008) [PubMed]  Article 
Target
Name:
IgG receptor FcRn large subunit p51
Synonyms:
FCGRN_HUMAN | FCGRT | FCRN
Type:
PROTEIN
Mol. Mass.:
39742.86
Organism:
Homo sapiens (Human)
Description:
ChEMBL_627631
Residue:
365
Sequence:
MGVPRPQPWALGLLLFLLPGSLGAESHLSLLYHLTAVSSPAPGTPAFWVSGWLGPQQYLSYNSLRGEAEPCGAWVWENQVSWYWEKETTDLRIKEKLFLEAFKALGGKGPYTLQGLLGCELGPDNTSVPTAKFALNGEEFMNFDLKQGTWGGDWPEALAISQRWQQQDKAANKELTFLLFSCPHRLREHLERGRGNLEWKEPPSMRLKARPSSPGFSVLTCSAFSFYPPELQLRFLRNGLAAGTGQGDFGPNSDGSFHASSSLTVKSGDEHHYCCIVQHAGLAQPLRVELESPAKSSVLVVGIVIGVLLLTAAAVGGALLWRRMRSGLPAPWISLRGDDTGVLLPTPGEAQDADLKDVNVIPATA
  
Inhibitor
Name:
BDBM50270959
Synonyms:
(2R)-2-{[(2S)-1-[(2S)-2-[(2S)-2-{2-[(3R)-3-[(2S)-2-[(2S)-2-{2-[(2S,3R)-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-phenylpropanamido]-3-methyl-3-sulfanylbutanamido]-3-hydroxybutanamido]acetamido}-3-(1H-imidazol-5-yl)propanamido]-3-phenylpropanamido]-2-oxopiperidin-1-yl]acetamido}-4-methylpentanamido]-3-(4-hydroxyphenyl)propanoyl]pyrrolidin-2-yl]formamido}-3-sulfanylpropanoic acid | CHEMBL524887
Type:
Small organic molecule
Emp. Form.:
C71H100N18O16S2
Mol. Mass.:
1525.795
SMILES:
CC(C)C[C@H](NC(=O)CN1CCC[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](N)CCCN=C(N)N)C(C)(C)S)[C@@H](C)O)C1=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(O)=O |r,wU:82.85,46.48,17.25,13.13,101.106,wD:4.4,61.64,50.60,42.44,74.78,28.36,97.103,(30.93,-20.12,;30.94,-18.58,;32.28,-17.82,;29.61,-17.81,;29.65,-16.27,;28.34,-15.46,;27.01,-16.23,;27.01,-17.77,;25.67,-15.46,;24.34,-16.23,;24.35,-17.76,;23.01,-18.53,;21.68,-17.76,;21.68,-16.22,;20.35,-15.45,;19.01,-16.22,;19.01,-17.76,;17.68,-15.45,;17.68,-13.91,;19.01,-13.14,;19.01,-11.6,;20.35,-10.83,;21.68,-11.6,;21.68,-13.14,;20.35,-13.91,;16.35,-16.22,;15.01,-15.45,;15.01,-13.91,;13.68,-16.22,;13.68,-17.76,;15.01,-18.53,;16.49,-18.09,;17.35,-19.37,;16.41,-20.59,;14.96,-20.06,;12.35,-15.45,;11.01,-16.22,;11.01,-17.76,;9.68,-15.45,;8.34,-16.22,;7,-15.45,;7,-13.91,;5.67,-16.22,;4.34,-15.45,;3,-16.22,;3,-17.76,;1.67,-15.45,;.34,-16.22,;-1,-15.45,;-1,-13.91,;-2.33,-16.22,;-2.33,-17.76,;-1,-18.53,;.34,-17.76,;1.67,-18.53,;1.67,-20.07,;.34,-20.84,;-1,-20.07,;-3.66,-15.45,;-5.01,-16.22,;-6.34,-15.45,;-5.01,-17.76,;-6.34,-18.53,;-3.66,-18.53,;-3.66,-20.07,;-5.01,-20.84,;-5.01,-22.38,;-6.34,-23.15,;-7.67,-22.38,;-6.34,-24.69,;1.67,-13.91,;1.66,-12.36,;3.21,-13.9,;.13,-13.92,;5.67,-17.76,;4.34,-18.53,;7,-18.53,;23.01,-15.45,;23.02,-13.91,;31.01,-15.53,;31.05,-13.99,;32.32,-16.33,;33.68,-15.6,;33.72,-14.06,;35.08,-13.32,;36.39,-14.13,;37.74,-13.39,;37.78,-11.85,;39.13,-11.12,;36.47,-11.05,;35.12,-11.78,;34.99,-16.4,;36.35,-15.67,;34.96,-17.94,;33.68,-18.82,;34.12,-20.3,;35.66,-20.34,;36.18,-18.89,;37.48,-18.06,;37.48,-16.52,;38.8,-18.84,;40.14,-18.08,;40.16,-16.54,;38.82,-15.76,;41.47,-18.86,;42.81,-18.1,;41.46,-20.4,)|
Structure:
Search PDB for entries with ligand similarity: